Jeff Schneble is the CEO of Human Interest, a San Francisco-based fintech company on a mission to close America's $28 trillion retirement savings gap by making 401(k) and 403(b) plans affordable and accessible for small and medium-sized businesses. A physicist turned venture capitalist turned operator, Schneble brought together a rare trifecta of academic rigor (PhD from Cambridge, MBA from Harvard), investment experience (Partner at Wing Venture Capital), and hands-on operational chops (Silver Lake Partners) before taking the helm at Human Interest in 2019. Under his leadership, the company has grown to serve over 45,000 companies, surpassed $200 million in ARR, raised over $1 billion in total funding at a $3 billion valuation, and is eyeing a public listing.
Francisco Leport is the co-founder and CEO of Gordian Biotechnology, a South San Francisco-based company pioneering high-throughput in vivo drug discovery for age-related diseases. Trained as a physicist at Stanford, Leport pivoted from particle physics and energy tech into biotech, driven by a lifelong fascination with longevity sparked by his mother's fruit fly research. Gordian's signature 'mosaic screening' platform uses gene therapy vectors and single-cell RNA sequencing to test hundreds of therapies simultaneously in single animal models, with an AI system called Pythia scoring results against human disease signatures - achieving 80% accuracy in predicting clinical outcomes. The company raised a $60M Series A in April 2024, backed by Founders Fund, Gigafund, and The Longevity Fund, and in early 2026 announced a research collaboration with Pfizer to accelerate obesity drug discovery.